Have any questions? 706-721-6582 or cts@augusta.edu
- BeiGene, Ltd. / “A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients With B-Cell Malignancies
Clinical Trial
BeiGene, Ltd. / “A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients With B-Cell Malignancies
This study will look at the safety and tolerability of an investigational anticancer drug currently known as BGB-16673 (?study drug?). This study aims to determine the range of BGB-16673 doses that can safely be used. This study will enroll participants with certain subtypes of non-Hodgkin Lymphoma
Eligibility Criteria
- Inclusion criteria: Must be 18 years of age or older Must have a confirmed diagnosis of any of these sub-types of Non-Hodgkins lymphoma: Marginal Zone Lymphoma (MZL); Follicular (FL); Relapsed or Refractory Mantle Cell Lymphoma (MCL); Relapsed or Refractory CLL/SLL; Relapsed or Refractory Waldensstrom Macroglobulinemia (WM); DLBCL; Richter's transformation to DLBCL ECOG status of 0 to 2 Must have adequate organ function Exclusion criteria: Had a prior Autologous stem cell transplant, unless greater than or equal to 3 months after transplant or has had an Allogeneic stem cell transplant less than or equal to 6 months before the first dose of the study drug. Had prior CAR-T unless greater than or equal to 6 months after cell infusion Is a pregnant or lactating female
RESEARCH. INNOVATION. DISCOVERY.